医学
心房颤动
随机对照试验
荟萃分析
秋水仙碱
内科学
梅德林
心脏病学
政治学
法学
作者
Xu Tian,Nan Zhang,Panagiotis Korantzopoulos,George Bazoukis,Κonstantinos P. Letsas,Gary Tse,Tong Liu
标识
DOI:10.1016/j.ijcard.2024.132068
摘要
Abstract
Background
Atrial fibrillation (AF), the most common arrhythmia, is closely related to inflammation. Colchicine has the potent anti-inflammatory effects. Several randomized clinical trials (RCTs) have evaluated the efficacy and safety of colchicine in the prevention of AF but the results are inconsistent. Objective
The purpose of our study was to evaluate the impact of colchicine on AF. Method and results
PubMed, EMBASE, Web of Science, Cochrane Library and ClinicalTrials.gov were searched for related studies until Jan 8, 2024. A total of 17 studies including 16,238 participants were included. Compared to the placebo group, there were fewer incidences of AF in the colchicine group (RR: 0.75, 95%CI: 0.68–0.83, P < 0.001). The incidence of overall adverse events and overall gastrointestinal intolerance did not differ significantly between the two groups. However, diarrhea, nausea, and discontinuation occurred more frequently in patients treated with colchicine. Conclusion
Colchicine can prevent patients from the incidence of AF, regardless of the mean age of patients, type of atrial fibrillation, maintenance dose, duration of colchicine use, cumulative daily dose, and follow-up time with more diarrhea, nausea and discontinuation. These adverse events can be avoided by low doses (0.5 mg once daily) and long period time of colchicine use.
科研通智能强力驱动
Strongly Powered by AbleSci AI